Cargando…

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2020
Materias:	Radiation Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574822/ https://www.ncbi.nlm.nih.gov/pubmed/33094066 http://dx.doi.org/10.7759/cureus.10525

Ejemplares similares

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer
por: Açikgoz, Yusuf, et al.
Publicado: (2020)

Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?
por: Ergun, Yakup, et al.
Publicado: (2020)

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
por: Karacin, Cengiz, et al.
Publicado: (2021)

Nutritional Health in Premenopausal Women: A Cross-Sectional Study from Turkey
por: Esen, Selin Akturk, et al.
Publicado: (2022)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
por: Esen, Selin Aktürk, et al.
Publicado: (2022)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After Curative Resection: A Real World Data
por: Caliskan Yildirim, Eda, et al.
Publicado: (2023)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients
por: Kos, Mehmet, et al.
Publicado: (2016)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

Health Literacy and Quality of Life in Patients With Type 1 Diabetes Mellitus
por: Esen, İrfan, et al.
Publicado: (2020)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Fatigue and depression in elderly patients with poorly controlled diabetes
por: Esen, Irfan, et al.
Publicado: (2022)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

“Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?
por: Karacin, Cengiz, et al.
Publicado: (2021)

Levels of Oxidized LDL, Estrogens, and Progesterone in Placenta Tissues and Serum Paraoxonase Activity in Preeclampsia
por: Açıkgöz, Şerefden, et al.
Publicado: (2013)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Relationship between Health Literacy and Medication Adherence of Turkish Cancer Patients Receiving Oral Chemotherapy
por: Gönderen Çakmak, Huri Seval, et al.
Publicado: (2020)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer
por: Karadag, Ibrahim, et al.
Publicado: (2023)

Arytenoid dislocation related to an uneventful endotracheal intubation: a case report
por: Senoglu, Nimet, et al.
Publicado: (2008)

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
por: Vogelzang, Nicholas J., et al.
Publicado: (2017)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
por: Guo, Jun, et al.
Publicado: (2018)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
por: Sheng, Xinan, et al.
Publicado: (2020)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8mcvp47mj03rkkn05nutb47ujd